



The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

CYCLOPHARM SIGNS 5-YEAR AGREEMENT WITH USA VETERANS ADMINISTRATION

14 March 2025 – Cyclopharm Limited (ASX: CYC) is pleased to announce that its Interim Agreement (IA) with the Veterans Health Administration (VA), announced on 3 October 2024, has successfully transitioned to a five-year Federal Supply Schedule (FSS) agreement.

The FSS agreement represents a significant milestone in expanding Technegas' adoption within the US federal healthcare system. It simplifies procurement processes for US federal agencies, including the 120 Veterans Administration (VA) hospitals, the Department of Defense (DoD), and Public Health Service (PHS) hospitals. By eliminating the need for individual contracts across the VA's 20 Regional Procurement Offices, this agreement enhances efficiency and ensures consistent supply of Technegas patient consumables.

Cyclopharm CEO James McBrayer stated: "*Securing this five-year Federal Supply Schedule agreement is a major achievement for Cyclopharm's expansion in the US market. This contract strengthens our partnership with the VA, underscores the clinical value of Technegas for US veterans, and streamlines access to our technology across federal healthcare facilities. We look forward to further accelerating adoption within the broader US Federal healthcare system.*"

As stated last month in the Company's full year results announcement, uncertainty around the evolving policy landscape in the US relating to healthcare funding may influence the timing of contract completion in the near term. "*Cyclopharm's confidence in the medium to long-term growth of Technegas within the VA system and other federal healthcare facilities remains unchanged. This five-year agreement reinforces our position as a trusted provider of nuclear medicine solutions and sets the foundation for continued success in the US market,*" Mr McBrayer said.

ENDS -

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director and CEO.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®

The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

In the United States the Technegas approved indication for use for use is:

TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), a radioactive diagnostic agent for use in adults and pediatric patients aged 6 years and older is for the visualization of pulmonary ventilation and the evaluation of pulmonary embolism when paired with perfusion imaging.